Young men are advised to delay hair transplants until after age 25, using finasteride, minoxidil, and dermarolling to manage hair loss. Concerns about unethical doctors highlight the need for careful planning.
A 21-year-old is frustrated with hair loss treatments, having used Rogaine and finasteride without success, and feels dermatologists are not providing straightforward advice. They plan to continue using finasteride and Rogaine, despite considering shaving their head due to low hair density.
A user's progress pictures and four month finasteride update showing dramatic hair regrowth, as well as their experiences with other treatments like minoxidil. The conversation also includes advice on diet, testosterone levels, and the importance of avoiding baldness for attraction and confidence.
The post and conversation are about microneedling as a treatment for alopecia. It provides a comprehensive review of scientific literature on the technique and its application.
A user who underwent a hair transplant in Istanbul to reduce balding, and the discussion of various treatments such as finasteride and growth hormone for preventing further hair loss.
How actor Ashton Kutcher used Dutasteride (Avodart) to treat his hair loss at age 25, but stopped taking it due to potential side effects when he wanted to have kids; and the discussion of various treatments for hair loss such as finasteride, minoxidil, and RU58841.
A user discusses starting finasteride for hair loss despite concerns about potential sexual side effects, emphasizing the psychological factors involved. Other users share mixed experiences, with some reporting no side effects and others experiencing issues.
The user uses finasteride, minoxidil, Nizoral, and dermarolling along with various supplements, oils, and shampoos to combat hair loss. They adjusted their routine based on feedback, changing dermarolling to once a week and reducing zinc intake due to side effects.
Treatments for hair loss, including microneedling (dermarolling and dermapen) and the use of minoxidil, finasteride, and RU58841. It provides detailed information about cost and usage of the various treatments, as well as potential side effects.
A double-blind clinical study that found ingestion of tocotrienols resulted in a 34.5% increase in hair regrowth compared to the placebo group, and discussion about potential side effects and cost of supplementation with vitamin E pills. The conversation noted that it may be more effective than commonly used treatments like minoxidil and finasteride.
Regrowing hairline without the use of Minoxidil or Finasteride, and instead using mechanical stimulation such as Derma Roller, Nizoral, Zinc Pyrithione, Scalp Massage, Scalp Exercise, Fish Oil and other topical solutions. It is cautioned that there are risks associated with not using medically-prescribed treatments, but it is suggested to consider mechanical stimulation in addition to those prescribed treatments.
Dutasteride is associated with increased blood glucose, HbA1c, LDL cholesterol, and liver enzyme activity, potentially leading to diabetes, NAFLD, and liver metabolism changes. The conversation highlights concerns about these adverse effects and calls for more studies, including on finasteride.
A user is concerned about starting finasteride due to negative reports and potential side effects. Other users suggest talking to a doctor, considering personal tolerance, and note that side effects are rare.
A user ordered H&W's 1.25% Topical Finasteride and is curious about others' experiences and side effects. Another user asked about availability in the US.
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
The user has been using 1mg Finasteride daily for six months, experiencing reduced shedding and itchiness but some frontal thinning. They are considering adding Minoxidil and have started dermarolling to enhance results.
The user is struggling with hair loss and has tried treatments like finasteride, minoxidil, and hair systems, each with drawbacks. They are considering retrying finasteride before a hair transplant and are advised to seek therapy for mental health support.
The conversation discusses a new liposomal topical finasteride from Hasson and Wong, available in Canada and Italy, soon in the US, costing $40/month. It claims to reduce scalp DHT by 50% without affecting serum DHT, potentially benefiting those who can't tolerate oral finasteride or RU58841.
A 21-year-old man shared his 2.5-year experience with hair loss treatments, including 1mg Propecia (finasteride) nightly, 12.5% Minoxidil once daily, 2% Nizoral shampoo 2-4 times a week, and later 5% Minoxidil once daily. He experienced minor side effects like watery semen and itchy scalp, and while he's seen fluctuations in hair growth, he's generally happy with the results and is considering experimental treatments like CB-03-01 and RU58841.
Fighting hair loss with "The Big 3" treatments of Propecia, Rogaine and Nizoral shampoo, as well as specific advice on how to use these products. People have shared their long-term success stories and some have discussed the side effects of finasteride. Other suggestions included Lipogaine and Pura D'or Hair Loss Prevention Therapy Shampoo & Conditioner.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.